First Relief Treatment for Peripheral Neuropathy
Launched by DYANSYS, INC. · May 16, 2018
Trial Information
Current as of June 18, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with Neuropathy pain
- Exclusion Criteria:
- • Patient with inbuilt pacemakers or any other devices which allows current into the body, pregnant ladies.
About Dyansys, Inc.
Dyansys, Inc. is a pioneering biotechnology company focused on developing innovative therapeutic solutions to address unmet medical needs. With a commitment to advancing healthcare through cutting-edge research and development, Dyansys leverages its expertise in neuromodulation and bioelectronic technologies to create impactful treatments for chronic conditions and neurological disorders. The company collaborates with leading academic institutions and clinical research organizations to ensure rigorous clinical trials and regulatory compliance, ultimately aiming to improve patient outcomes and enhance quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Warangal, Telangana, India
Patients applied
Trial Officials
Dr. Gurunath, Ph.D
Study Director
Jeevak hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials